PIDOGREL 75 MG BT 30
Product informations
Clopidogrel is indicated for the prevention of events related to atherothrombosis:
- In patients with a recent myocardial infarction (within a few days up to 35 days), stroke (within 7 days to less than 6 months), or established peripheral arterial disease.
- In patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-Q-wave myocardial infarction), in combination with acetylsalicylic acid (ASA).
- In acute ST-segment elevation myocardial infarction, in combination with ASA in medically treated patients who are eligible for thrombolytic therapy.
- For prevention of atherothrombotic and thromboembolic events in atrial fibrillation in adult patients with atrial fibrillation who have at least one risk factor for vascular events that cannot be treated with vitamin K antagonists (VKAs) and have a low risk of bleeding, Clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.